Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Observation × Endocrine × Clear all

Status

Not yet recruiting 2 Completed 2 Terminated 1 Recruiting 1

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 18 Thoracic 6 Gynecologic 6 Breast 6 Lymphoid 5 Head & Neck 5 Sarcoma 4 CNS 4 Tumor-Agnostic 3 Genitourinary 3 Other hematologic neoplasm 2 Other 2 Dermatologic 2 Plasma cell 1 Other solid neoplasm 1 Endocrine 1

Conditions

Insulinoma 1 Hyperaldosteronism 1

Interventions

lutetium Lu 177 dotatate 14 Magnetic Resonance Spectroscopy 13 gallium Ga 68 dotatate 8 Specimen Handling 8 Everolimus 8 pembrolizumab 7 Cisplatin 7 cabozantinib 5 Etoposide 5 177Lu-octreotide, DOTA(0)-Tyr(3)- 5 lanreotide 4 Fluorodeoxyglucose F18 4 trametinib 3 surufatinib 3 olaparib 3 lenvatinib 3 fluorodopa F 18 3 dabrafenib 3 cemiplimab 3 X-Rays 3 Transurethral Resection of Prostate 3 Thyrotropin Alfa 3 Somatostatin 3 Nivolumab 3 Lutetium-177 3 Iodine-131 3 Injections 3 Drug Therapy 3 Cyclophosphamide 3 Carboplatin 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07272187 2025-12-09

EURAGIL

Herlev Hospital

Hyperaldosteronism, Insulinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡